Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCCLillian L. Siu, Jérôme Fayette, J. Armstrong et al.|JAMA Oncology|2018Cited by 315
The evolving landscape of brain metastasis: volume IIManuel Valiente, Johanna A. Joyce, Carey K. Anders et al.|Trends in cancer|2025Cited by 9
Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.Elisa Fontana, Ramy Saleh, Aakash Desai et al.|Journal of Clinical Oncology|2025Cited by 2
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumorsDiogo Martins-Branco, Nuria Kotecki, Guilherme Nader Marta et al.|Nature Medicine|2023Cited by 2
Abstract CT202: CSFctDNA as a surrogate for tumor tissue DNA in BC pts with CNS metastases: First results from the Brainstorm program (Oncodistinct 006)Nuria Kotecki, Ahmad Awada, Diogo Martins-Branco et al.|Cancer Research|2024Cited by 1